Characteristics and Outcomes of Myelodysplastic Syndrome Patients Treated With Darbepoetin Alfa for Anemia in Turkey: A Multicenter Retrospective Study

被引：0

作者：

Acar, Ibrahim Halil ^{[1
]}

Atalay, Figen ^{[2
]}

Demirsoy, Esra Terzi ^{[3
]}

Can, Ferda ^{[4
]}

Guven, Zeynep Tugba ^{[5
]}

Cetiner, Mustafa ^{[6
]}

Tombak, Anil ^{[7
]}

Comert, Melda ^{[8
]}

Guvenc, Birol ^{[1
]}

机构：

[1] Cukurova Univ, Dept Hematol, Dept Internal Med, Fac Med, Adana, Turkiye

[2] Baskent Univ, Istanbul Hosp, Hematol Clin, Ankara, Turkiye

[3] SBU Kocaeli Derince Training & Res Hosp, Hematol Clin, Kocaeli, Turkiye

[4] Ankara City Hosp, Hematol Clin, Ankara, Turkiye

[5] Erciyes Univ, Dept Hematol, Dept Internal Med, Fac Med, Kayseri, Turkiye

[6] Acibadem Maslak Hosp, Hematol Clin, Istanbul, Turkiye

[7] Mersin Univ, Dept Hematol, Dept Internal Med, Fac Med, Mersin, Turkiye

[8] SBU Gulhane Training & Res Hosp, Hematol Clin, Istanbul, Turkiye

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MDS; myelodysplastic syndrome; darbepoetin alfa;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-143

引用

页码：S354 / S354

页数：1

共 50 条

[1] Darbepoetin alfa for anemia with myelodysplastic syndrome
Seastone, David J.
Gerds, Aaron T.
[J]. EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (02) : 139 - 146
[2] Darbepoetin alfa for the treatment of anemia in patients with myelodysplastic syndrome.
Giraldo, P
Nomdedeu, B
Loscertales, J
Requena, C
de Paz, R
Tormo, M
Navarro, P
Benedit, P
Gasquet, JA
[J]. BLOOD, 2005, 106 (11) : 714A - 714A
[3] Effectiveness of darbepoetin alfa vs epoetin alfa in patients with anemia resulting from myelodysplastic syndrome (MDS): results of a retrospective cohort study.
Patten, JE
Sullivan, T
Mun, Y
Wallace, J
[J]. PHARMACOTHERAPY, 2005, 25 (03): : 468 - 468
[4] Retrospective study of the appropriate utilization of epoetin alfa and darbepoetin alfa in cancer patients with anemia
Wong, SF
Brown, ML
Sarkisian, R
[J]. PHARMACOTHERAPY, 2004, 24 (10): : 1452 - 1452
[5] A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Schwartzberg, L
Shiffman, R
Tomita, D
Stolshek, B
Rossi, G
Adamson, R
[J]. CLINICAL THERAPEUTICS, 2003, 25 (11) : 2781 - 2796
[6] Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: A retrospective cohort study
Nurko, Saul
Spirko, Rita
Law, Amy
Dennis, Vincent W.
[J]. CLINICAL THERAPEUTICS, 2007, 29 (09) : 2010 - 2021
[7] Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa.
Fahrbach, KR
Frame, D
Scheye, R
Fastenau, JM
Drielick, M
Piech, CT
Nalysnyk, L
[J]. BLOOD, 2003, 102 (11) : 510B - 511B
[8] Epoetin alfa and darbepoetin alfa anemia treatment outcomes in cancer patients from a VA perspective
Papatheofanis, FJ
Fastenau, JM
Chiang, T
Piech, CT
[J]. VALUE IN HEALTH, 2004, 7 (03) : 246 - 246
[9] Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
Abaza, Yasmin
Xie, Zhuoer
Burkart, Madelyn
Badar, Talha
Desai, Pinkal
Shallis, Rory M.
Patel, Anand Ashwin
Cohen-Nowak, Adam
Oh, Timothy S.
Walker, Chelsea
Easwar, Neela
Kewan, Tariq
Cannova, Joseph
Bell-Burdett, Kirsten
Al Ali, Najla H.
Sallman, David A.
Roboz, Gail J.
Carraway, Hetty E.
Zeidan, Amer M.
Patnaik, Mrinal M.
Altman, Jessica K.
Komrokji, Rami S.
[J]. BLOOD, 2023, 142
[10] Hematologic outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients with anemia: results of the Dosing and Outcomes Study of Erythropoiesis Stimulating Therapies (DOSE Registry).
Memisoglu, A
Peake, C
Vichare, R
McKenzie, RS
Howell, J
Piech, CT
[J]. PHARMACOTHERAPY, 2005, 25 (10): : 1469 - 1469

← 1 2 3 4 5 →